vs
Adaptive Biotechnologies Corp（ADPT）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
RESOURCES CONNECTION, INC.的季度营收约是Adaptive Biotechnologies Corp的1.6倍（$117.7M vs $71.7M），RESOURCES CONNECTION, INC.净利率更高（-10.8% vs -18.9%，领先8.2%），Adaptive Biotechnologies Corp同比增速更快（51.0% vs -19.2%），RESOURCES CONNECTION, INC.自由现金流更多（$15.6M vs $1.4M），过去两年Adaptive Biotechnologies Corp的营收复合增速更高（30.8% vs -11.8%）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
ADPT vs RGP — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $117.7M |
| 净利润 | $-13.6M | $-12.7M |
| 毛利率 | 74.6% | 37.1% |
| 营业利润率 | -17.8% | -10.3% |
| 净利率 | -18.9% | -10.8% |
| 营收同比 | 51.0% | -19.2% |
| 净利润同比 | 59.7% | 81.6% |
| 每股收益（稀释后） | $-0.08 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $71.7M | $117.7M | ||
| Q3 25 | $94.0M | $120.2M | ||
| Q2 25 | $58.9M | $139.3M | ||
| Q1 25 | $52.4M | $129.4M | ||
| Q4 24 | $47.5M | $145.6M | ||
| Q3 24 | $46.4M | $136.9M | ||
| Q2 24 | $43.2M | $148.2M | ||
| Q1 24 | $41.9M | $151.3M |
| Q4 25 | $-13.6M | $-12.7M | ||
| Q3 25 | $9.5M | $-2.4M | ||
| Q2 25 | $-25.6M | $-73.3M | ||
| Q1 25 | $-29.9M | $-44.1M | ||
| Q4 24 | $-33.7M | $-68.7M | ||
| Q3 24 | $-32.1M | $-5.7M | ||
| Q2 24 | $-46.2M | $10.5M | ||
| Q1 24 | $-47.5M | $2.5M |
| Q4 25 | 74.6% | 37.1% | ||
| Q3 25 | 80.7% | 39.5% | ||
| Q2 25 | 69.4% | 40.2% | ||
| Q1 25 | 67.6% | 35.1% | ||
| Q4 24 | 62.0% | 38.5% | ||
| Q3 24 | 64.1% | 36.5% | ||
| Q2 24 | 55.3% | 40.2% | ||
| Q1 24 | 56.9% | 37.0% |
| Q4 25 | -17.8% | -10.3% | ||
| Q3 25 | 10.9% | -1.7% | ||
| Q2 25 | -42.5% | -47.0% | ||
| Q1 25 | -56.4% | -38.4% | ||
| Q4 24 | -71.3% | -52.7% | ||
| Q3 24 | -70.3% | -3.5% | ||
| Q2 24 | -109.6% | 7.6% | ||
| Q1 24 | -116.5% | 2.8% |
| Q4 25 | -18.9% | -10.8% | ||
| Q3 25 | 10.2% | -2.0% | ||
| Q2 25 | -43.5% | -52.6% | ||
| Q1 25 | -56.9% | -34.0% | ||
| Q4 24 | -71.0% | -47.2% | ||
| Q3 24 | -69.1% | -4.2% | ||
| Q2 24 | -107.0% | 7.1% | ||
| Q1 24 | -113.5% | 1.7% |
| Q4 25 | $-0.08 | $-0.38 | ||
| Q3 25 | $0.06 | $-0.07 | ||
| Q2 25 | $-0.17 | $-2.21 | ||
| Q1 25 | $-0.20 | $-1.34 | ||
| Q4 24 | $-0.22 | $-2.08 | ||
| Q3 24 | $-0.22 | $-0.17 | ||
| Q2 24 | $-0.31 | $0.31 | ||
| Q1 24 | $-0.33 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $89.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $218.8M | $194.6M |
| 总资产 | $512.7M | $289.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $70.5M | $89.8M | ||
| Q3 25 | $55.0M | $77.5M | ||
| Q2 25 | $43.2M | $86.1M | ||
| Q1 25 | $50.6M | $72.5M | ||
| Q4 24 | $47.9M | $78.2M | ||
| Q3 24 | $38.1M | $89.6M | ||
| Q2 24 | $59.8M | $108.9M | ||
| Q1 24 | $71.2M | $113.8M |
| Q4 25 | $218.8M | $194.6M | ||
| Q3 25 | $204.4M | $206.4M | ||
| Q2 25 | $179.7M | $207.1M | ||
| Q1 25 | $190.4M | $277.8M | ||
| Q4 24 | $202.7M | $325.7M | ||
| Q3 24 | $223.8M | $407.2M | ||
| Q2 24 | $241.6M | $418.8M | ||
| Q1 24 | $274.9M | $414.9M |
| Q4 25 | $512.7M | $289.3M | ||
| Q3 25 | $490.6M | $287.2M | ||
| Q2 25 | $496.6M | $304.7M | ||
| Q1 25 | $510.9M | $375.6M | ||
| Q4 24 | $539.4M | $424.9M | ||
| Q3 24 | $558.5M | $512.9M | ||
| Q2 24 | $584.9M | $510.9M | ||
| Q1 24 | $620.3M | $523.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | $15.6M |
| 自由现金流率自由现金流/营收 | 2.0% | 13.2% |
| 资本支出强度资本支出/营收 | 0.9% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-48.9M | $24.3M |
8季度趋势，按日历期对齐
| Q4 25 | $2.1M | $15.9M | ||
| Q3 25 | $-7.1M | $-7.8M | ||
| Q2 25 | $-12.4M | $16.8M | ||
| Q1 25 | $-28.5M | $659.0K | ||
| Q4 24 | $-12.5M | $1.8M | ||
| Q3 24 | $-27.1M | $-309.0K | ||
| Q2 24 | $-17.3M | $3.2M | ||
| Q1 24 | $-38.4M | $20.5M |
| Q4 25 | $1.4M | $15.6M | ||
| Q3 25 | $-7.5M | $-8.0M | ||
| Q2 25 | $-13.1M | $16.5M | ||
| Q1 25 | $-29.7M | $238.0K | ||
| Q4 24 | $-12.6M | $61.0K | ||
| Q3 24 | $-27.4M | $-575.0K | ||
| Q2 24 | $-19.0M | $3.0M | ||
| Q1 24 | $-39.9M | $20.4M |
| Q4 25 | 2.0% | 13.2% | ||
| Q3 25 | -8.0% | -6.6% | ||
| Q2 25 | -22.2% | 11.8% | ||
| Q1 25 | -56.7% | 0.2% | ||
| Q4 24 | -26.5% | 0.0% | ||
| Q3 24 | -59.0% | -0.4% | ||
| Q2 24 | -44.1% | 2.1% | ||
| Q1 24 | -95.2% | 13.5% |
| Q4 25 | 0.9% | 0.3% | ||
| Q3 25 | 0.4% | 0.1% | ||
| Q2 25 | 1.1% | 0.2% | ||
| Q1 25 | 2.4% | 0.3% | ||
| Q4 24 | 0.2% | 1.2% | ||
| Q3 24 | 0.7% | 0.2% | ||
| Q2 24 | 4.0% | 0.1% | ||
| Q1 24 | 3.6% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | — | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
